Epitope-based vaccines: An update on epitope identification, vaccine design and delivery

Current Opinion in Immunology

Volumn 15, Issue 4, 2003, Pages 461-470

  Sette, Alessandro ^a   Fikes, John ^b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b Epimmune   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

CARCINOMA; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; IMMUNOGENICITY; REVIEW; T LYMPHOCYTE; VACCINATION;

EID: 0041402836     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(03)00083-9     Document Type: Review

References (133)

1. Sette A., Newman M., Livingston B., McKinney D., Sidney J., Ishioka G., Tangri S., Alexander J., Fikes J., Chesnut R. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens. 59:2002;443-451.
2. Sette A., Keogh E., Ishioka G., Sidney J., Tangri S., Livingston B., McKinney D., Newman M., Chesnut R., Fikes J. Epitope identification and vaccine design for cancer immunotherapy. Curr. Opin. Invest Drugs. 3:2002;132-139.
3. Chen W., Anton L.C., Bennink J.R., Yewdell J.W. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity. 12:2000;83-93.
4. van der Most R.G., Sette A., Oseroff C., Alexander J., Murali-Krishna K., Lau L.L., Southwood S., Sidney J., Chesnut R.W., Matloubian M., Ahmed R. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J. Immunol. 157:1996;5543-5554.
5. Vitiello A., Yuan L., Chesnut R.W., Sidney J., Southwood S., Farness P., Jackson M.R., Peterson P.A., Sette A. Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J. Immunol. 157:1996;5555-5562.
6. Yewdell J.W., Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:1999;51-88.
7. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine. 19:2001;4652-4660.
8. Le T.T., Drane D., Malliaros J., Cox J.C., Rothel L., Pearse M., Woodberry T., Gardner J., Suhrbier A. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine. 19:2001;4669-4675.
9. Peter K., Men Y., Pantaleo G., Gander B., Corradin G. Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. Vaccine. 19:2001;4121-4129.
10. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K.M., Bhardwaj N.et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61:2001;6451-6458.
11. Velazquez C., Vidavsky I., van der Drift K., Gross M.L., Unanue E.R. Chemical identification of a low abundance lysozyme peptide family bound to I-Ak histocompatibility molecules. J. Biol. Chem. 277:2002;42514-42522.
12. Chen W., Bennink J.R., Morton P.A., Yewdell J.W. Mice deficient in perforin, CD4+ T cells, or CD28-mediated signaling maintain the typical immunodominance hierarchies of CD8+ T-cell responses to influenza virus. J. Virol. 76:2002;10332-10337 A key study that makes a start of defining the molecular mechanisms underlying immunodominance.
13. DiPaolo R.J., Unanue E.R. Cutting edge: the relative distribution of T cells responding to chemically dominant or minor epitopes of lysozyme is not affected by CD40-CD40 ligand and B7-CD28-CTLA-4 costimulatory pathways. J. Immunol. 169:2002;2832-2836.
14. Rodriguez F., Harkins S., Slifka M.K., Whitton J.L. Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J. Virol. 76:2002;4251-4259 This study is an important contribution to the definition of the mechanisms of immunodominance, and its possible implications for vaccine development.
15. Palmowski M.J., Choi E.M., Hermans I.F., Gilbert S.C., Chen J.L., Gileadi U., Salio M., Van Pel A., Man S., Bonin E.et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168:2002;4391-4398.
16. ••].
17. ••], this review is an important reminder of the crucial role of the composition of the T-cell repertoire in shaping immunodominance.
18. Brehm M.A., Pinto A.K., Daniels K.A., Schneck J.P., Welsh R.M., Selin L.K. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat. Immunol. 3:2002;627-634.
19. Slifka M.K., Blattman J.N., Sourdive D.J., Liu F., Huffman D.L., Wolfe T., Hughes A., Oldstone M.B., Ahmed R., Von Herrath M.G. Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy. J. Immunol. 170:2003;1231-1239.
20. Kjer-Nielsen L., Clements C.S., Purcell A.W., Brooks A.G., Whisstock J.C., Burrows S.R., McCluskey J., Rossjohn J. A structural basis for the selection of dominant alphabeta T cell receptors in antiviral immunity. Immunity. 18:2003;53-64 This is a key paper, pointing out the importance of the structural features of epitope-MHC complexes in determining immunodominance.
21. Gray P.M., Parks G.D., Alexander-Miller M.A. High avidity CD8+ T cells are the initial population elicited following viral infection of the respiratory tract. J. Immunol. 170:2003;174-181.
22. Yu X.G., Addo M.M., Rosenberg E.S., Rodriguez W.R., Lee P.K., Fitzpatrick C.A., Johnston M.N., Strick D., Goulder P.J., Walker B.D., Altfeld M. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J. Virol. 76:2002;8690-8701.
23. Hollsberg P. Contribution of HLA class I allele expression to CD8+ T-cell responses against Epstein-Barr virus. Scand. J. Immunol. 55:2002;189-195.
24. Belz G.T., Stevenson P.G., Doherty P.C. Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza A viruses. J. Immunol. 165:2000;2404-2409.
25. Belz G.T., Xie W., Doherty P.C. Diversity of epitope and cytokine profiles for primary and secondary influenza a virus-specific CD8+ T cell responses. J. Immunol. 166:2001;4627-4633.
26. Smith S.G., Patel P.M., Porte J., Selby P.J., Jackson A.M. Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Clin. Cancer Res. 7:2001;4253-4261.
27. van der Burg S.H., Ressing M.E., Kwappenberg K.M., de Jong A., Straathof K., de Jong J., Geluk A., van Meijgaarden K.E., Franken K.L., Ottenhoff T.H.et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int. J. Cancer. 91:2001;612-618.
28. Voo K.S., Fu T., Heslop H.E., Brenner M.K., Rooney C.M., Wang R.-F. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4+ T cells. Cancer Res. 62:2002;7195-7199.
29. Marttila J., Hyöty H., Vilja P., Härkönen T., Alho A., Roivainen M., Hyypiä T., Ilonen J. T cell epitopes in coxsackievirus B4 structural proteins concentrate in eegions conserved between enteroviruses. Virology. 293:2002;217-224.
30. Omiya R., Buteau C., Kobayashi H., Paya C.V., Celis E. Inhibition of EBV-induced lymphoproliferation by CD4+ T cells specific for an MHC class II promiscuous epitope. J. Immunol. 169:2002;2172-2179.
31. Pancre V., Georges B., Angyalosi G., Castelli F., Delanoye A., Delacre M., Hachulla E., Maillere B., Bouzidi A., Auriault C. Novel promiscuous HLA-DQ HIV Nef peptide that induces IFN-gamma-producing memory CD4+ T cells. Clin. Exp. Immunol. 129:2002;429-437 The first description of a HLA-DQ-restricted promiscuous HIV epitope.
32. Panigada M., Sturniolo T., Besozzi G., Boccieri M.G., Sinigaglia F., Grassi G.G., Grassi F. Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins. Infect Immun. 70:2002;79-85.
33. Doolan D.L., Southwood S., Chesnut R., Appella E., Gomez E., Richards A., Higashimoto Y.I., Maewal A., Sidney J., Gramzinski R.A.et al. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J. Immunol. 165:2000;1123-1137.
34. Wilson C.C., Palmer B., Southwood S., Sidney J., Higashimoto Y., Appella E., Chesnut R., Sette A., Livingston B.D. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J. Virol. 75:2001;4195-4207.
35. Rudolf M.P., Man S., Melief C.J., Sette A., Kast W.M. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin. Cancer Res. 7:2001;788s-795s.
36. Monroy-Garcia A., Weiss-Steider B., Hernandez-Montes J., Ortiz-Navarrete V.F., Banuelos-Panuco A., Acosta-Araujo A., Diaz-Quinonez A., Lopez-Graniel C.M., Herbert G., Granados J.et al. Identification of two homologous antigenic peptides derived from L1 HPV-16 and 18 proteins specific for the HLA-B*3901 allele. Arch Virol. 147:2002;1933-1942.
37. Kather A., Ferrara A., Nonn M., Schinz M., Nieland J., Schneider A., Durst M., Kaufmann A.M. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination. Int. J. Cancer. 104:2003;345-353.
38. Wizel B., Starcher B.C., Samten B., Chroneos Z., Barnes P.F., Dzuris J., Higashimoto Y., Appella E., Sette A. Multiple chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen. J. Immunol. 169:2002;2524-2535.
39. Caccamo N., Milano S., Di Sano C., Cigna D., Ivanyi J., Krensky A.M., Dieli F., Salerno A. Identification of epitopes of Mycobacterium tuberculosis 16-kDa protein recognized by human leukocyte antigen-A*0201 CD8(+) T lymphocytes. J. Infect Dis. 186:2002;991-998.
40. Akiyama Y., Maruyama K., Mochizuki T., Sasaki K., Takaue Y., Yamaguchi K. Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus. Immunol. Lett. 83:2002;21-30.
41. Frankenberg N., Pepperl-Klindworth S., Meyer R.G., Plachter B. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology. 295:2002;208-216.
42. Micheletti F., Monini P., Fortini C., Rimessi P., Bazzaro M., Andreoni M., Giuliani M., Traniello S., Ensoli B., Gavioli R. Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. Immunology. 106:2002;395-403.
43. Wang Q.J., Huang X.-L., Rappocciolo G., Jenkins F.J., Hildebrand W.H., Fan Z., Thomas E.K., Rinaldo C.R. Jr. Identification of an HLA A*0201-restricted CD8+ T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood. 99:2002;3360-3366.
44. Altfeld M.A., Livingston B., Reshamwala N., Nguyen P.T., Addo M.M., Shea A., Newman M., Fikes J., Sidney J., Wentworth P.et al. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J. Virol. 75:2001;1301-1311.
45. Currier J.R., deSouza M., Chanbancherd P., Bernstein W., Birx D.L., Cox J.H. Comprehensive screening for human Immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -CW0304 alleles. J. Virol. 76:2002;4971-4986.
46. MacDonald K.S., Matukas L., Embree J.E., Fowke K., Kimani J., Nagelkerke N.J., Oyugi J., Kiama P., Kaul R., Luscher M.A.et al. Human leucocyte antigen supertypes and immune susceptibility to HIV-1, implications for vaccine design. Immunol. Lett. 79:2001;151-157.
47. Novitsky V., Rybak N., McLane M.F., Gilbert P., Chigwedere P., Klein I., Gaolekwe S., Chang S.Y., Peter T., Thior I. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J. Virol. 75:2001;9210-9228.
48. Urbani S., Uggeri J., Matsuura Y., Miyamura T., Penna A., Boni C., Ferrari C. Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. Hepatology. 33:2001;1533-1543.
49. Sarobe P., Huarte E., Lasarte J.J., Lopez-Diaz de Cerio A., Garcia N., Borras-Cuesta F., Prieto J. Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes. J. Hepatol. 34:2001;321-329.
50. Thimme R., Chang K.M., Pemberton J., Sette A., Chisari F.V. Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLA-B51. J. Virol. 75:2001;3984-3987.
51. Andersen M.H., Pedersen L.Ø., Becker J.C., Straten P.T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61:2000;869-872.
52. Azuma T., Makita M., Ninomiya K., Fujita S., Harada M., Yasukawa M. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br. J. Haematol. 116:2002;601-603.
53. Andersen M.H., Pedersen L.Ø., Capeller B., Bröcker E.-B., Becker J.C., Straten P.T. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 61:2001;5964-5968.
54. Ferries E., Connan F., Pages F., Gaston J., Hagnere A.M., Vieillefond A., Thiounn N., Guillet J., Choppin J. Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer. Hum. Immunol. 62:2001;791-798.
55. Keogh E., Fikes J., Southwood S., Celis E., Chesnut R., Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J. Immunol. 167:2001;787-796.
56. Schmitz J., Reali E., Hodge J.W., Patel A., Davis G., Schlom J., Greiner J.W. Identification of an interferon-inducible carcinoembryonic antigen (CEA) CD8+ T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res. 62:2002;5058-5064.
57. Scardino A., Alves P., Gross D.A., Tourdot S., Graff-Dubois S., Angevin E., Firat H., Chouaib S., Lemonnier F., Nadler L.M.et al. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur. J. Immunol. 31:2001;3261-3270.
58. Umano Y., Tsunoda T., Tanaka H., Matsuda K., Yamaue H., Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br. J. Cancer. 84:2001;1052-1057.
59. Tanaka H., Tsunoda T., Nukaya I., Sette A., Matsuda K., Umano Y., Yamaue H., Takesako K., Tanimura H. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumor-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. Br. J. Cancer. 84:2001;94-99.
60. Kessler J.H., Beekman N.J., Bres-Vloemans S.A., Verdijk P., van Veelen P.A., Kloosterman-Joosten A.M., Vissers D.C., ten Bosch G.J., Kester M.G., Sijts A.et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193:2001;73-88.
61. Riley J.P., Rosenberg S.A., Parkhurst M.R. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. J. Immunother. 24:2001;212-220.
62. Kiessling A., Schmitz M., Stevanovic S., Weigle B., Holig K., Fussel M., Fussel S., Meye A., Wirth M.P., Rieber E.P. Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int. J. Cancer. 102:2002;390-397.
63. Lu J., Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res. 62:2002;5807-5812 An important study, greatly enhancing the number of epitopes available for study in the context of human prostate tumors.
64. Francini G., Scardino A., Kosmatopoulos K., Lemonnier F.A., Campoccia G., Sabatino M., Pozzessere D., Petrioli R., Lozzi L., Neri P.et al. High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J. Immunol. 169:2002;4840-4849.
65. Okano F., Storkus W.J., Chambers W.H., Pollack I.F., Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor 2 chain. Clin. Cancer Res. 8:2002;2851-2855.
66. Konopitzky R., König U., Meyer R.G., Sommergruber W., Wölfel T., Tamás Schweighoffer T. Identification of HLA-A*0201-restricted T cell epitopes derived from the novel overexpressed tumor antigen calcium-activated chloride channel 2. J. Immunol. 169:2002;540-547.
67. Jaramillo A., Majumder K., Manna P.P., Fleming T.P., Doherty G., Dipersio J.F., Mohanakumar T. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int. J. Cancer. 102:2002;499-506.
68. Harashima N., Tanaka K., Sasatomi T., Shimizu K., Miyagi Y., Yamada A., Tamura M., Yamana H., Itoh K., Shichijo S. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur. J. Immunol. 31:2001;323-332.
69. Wang R.F. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol. Rev. 188:2002;65-80 A good review of tumor-associated helper epitopes.
70. Linard B., Bezieau S., Benlalam H., Labarriere N., Guilloux Y., Diez E., Jotereau F. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J. Immunol. 168:2002;4802-4808.
71. Lauemoller S.L., Kesmir C., Corbet S.L., Fomsgaard A., Holm A., Claesson M.H., Brunak S., Buus S. Identifying cytotoxic T cell epitopes from genomic and proteomic information: The human MHC project. Rev. Immunogenet. 2:2000;477-491.
72. Wang R.F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22:2001;269-276.
73. Topalian S.L., Gonzales M.I., Ward Y., Wang X., Wang R.-F. Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. Cancer Res. 62:2002;5505-5509.
74. Housseau F., Moorthy A., Langer D.A., Robbins P.F., Gonzales M.I., Topalian S.L. N-linked carbohydrates in tyrosinase are required for its recognition by human MHC class II-restricted CD4+ T cells. Eur. J. Immunol. 31:2001;2690-2701.
75. Zeng G., Wang X., Robbins P.F., Rosenberg S.A., Wang R.-F. CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. U.S.A. 98:2001;3964-3969.
76. Zarour H.M., Maillere B., Brusic V., Coval K., Williams E., Pouvelle-Moratille S., Castelli F., Land S., Bennouna J., Logan T., Kirkwood J.M. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 62:2002;213-218.
77. Kierstead L.S., Ranieri E., Olson W., Brusic V., Sidney J., Sette A., Kasamon Y.L., Slingluff C.L., Kirkwood J.M., Storkus W.J. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br. J. Cancer. 85:2001;1738-1745.
78. Chaux P., Lethé B., Van Snick J., Corthals J., Schultz E.S., Cambiaso C.L., Boon T., van der Bruggen P. A MAGE-1 peptide recognized on HLA-DR15 by CD4+ T cells. Eur. J. Immunol. 31:2001;1910-1916.
79. Kobayashi H., Song Y., Hoon D.S.B., Appella E., Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res. 61:2001;4773-4778.
80. Consogno G., Manici S., Facchinetti V., Bachi A., Hammer J., Conti-Fine B.M., Rugarli C., Traversari C., Pia Protti M. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood. 101:2003;1038-1044.
81. McNeel D.G., Nguyen L.D., Disis M.L. Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res. 61:2001;5161-5167.
82. Hural J.A., Friedman R.S., McNabb A., Steen S.S., Henderson R.A., Kalos M. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J. Immunol. 169:2002;557-565.
83. Kobayashi H., Omiya R., Ruiz M., Huarte E., Sarobe P., Lasarte J.J., Herraiz M., Sangro B., Prieto J., Borras-Cuesta F., Celis E. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin. Cancer Res. 8:2002;3219-3225.
84. Schroers R., Huang X.F., Hammer J., Zhang J., Chen S.-Y. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 62:2002;2600-2605.
85. Vissers J.L.M., de Vries I.J.M., Engelen L.P.H., Scharenborg N.M., Molkenboer J., Figdor C.G., Oosterwijk E., Adema G.J. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-dr molecules to CD4+ T lymphocytes. Int. J. Cancer. 100:2002;2441-2444.
86. Zeng G., Li Y., El-Gamil M., Sidney J., Sette A., Wang R.-F., Rosenberg S.A., Robbins P.F. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62:2002;3630-3635.
87. Knutson K.L., Schiffman K., Disis M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107:2001;477-484.
88. Kobayashi H., Lu J., Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 61:2001;7577-7584.
89. La Rosa C., Krishnan R., Markel S., Schneck J.P., Houghten R., Pinilla C., Diamond D.J. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood. 97:2001;1776-1786.
90. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A., Davis M.M., Engleman E.G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8809-8814.
91. Yang S., Linette G.P., Longerich S., Haluska F.G. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J. Immunol. 169:2002;531-539.
92. Hoffmann T.K., Loftus D.J., Nakano K., Maeurer M.J., Chikamatsu K., Appella E., Whiteside T.L., DeLeo A.B. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53264-272 epitope. J. Immunol. 168:2002;1338-1347.
93. Baratin M., Kayibanda M., Ziol M., Romieu R., Briand J.P., Guiller J.G., Viguier M. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumor epitope. J. Pept. Sci. 8:2002;327-334.
94. Palermo B., Campanelli R., Garbelli S., Mantovani S., Robustelli della Cuna G., Necker A., Manganoni A.M., Carella G., Rivoltini L., Lantelme E., Giachino C. Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis. Melanoma Res. 12:2002;491-498.
95. Pinilla C., Rubio-Godoy V., Dutoit V., Guillaume P., Simon R., Zhao Y., Houghten R.A., Cerottini J.-C., Romero P., Valmori D. Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. Cancer Res. 61:2001;5153-5160.
96. Graff-Dubois S., Faure O., Gross D.-A., Alves P., Scardino A., Chouaib S., Lemonnier F.A., Kosmatopoulos K. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J. Immunol. 169:2002;575-580.
97. BenMohamed L., Wechsler S.L., Nesburn A.B. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infec. Dis. 2:2002;425.
98. Deliyannis G., Jackson D.C., Ede N.J., Zeng W., Hourdakis I., Sakabetis E., Brown L.E. Induction of long-term memory CD8+ T cells for recall of viral clearing responses against influenza virus. J. Virol. 76:2002;4212-4221.
99. Le Gal F.-A., Prevost-Blondel A., Lengagne R., Bossus M., Farace F., Chaboissier A., Gras-Masse H., Engelhard V.H., Guillet J.-G., Gahéry-Ségard H. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study. Int. J. Cancer. 98:2002;221-227.
100. Zeng W., Ghosh S., Lau Y.F., Brown L.E., Jackson D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. 169:2002;4905-4912.
101. Gras-Masse H. Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations. Mol. Immunol. 38:2001;423-431.
102. Pialoux G., Gahéry-Ségard H., Sermet S., Poncelet H., Fournier S., Gérard L., Tartar A., Gras-Masse H., Levy J.P., Guillet J.P.J. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS J. 15:2001;1239-1250.
103. Sadler K., Tam J.P. Peptide dendrimers: applications and synthesis. J. Biotechnol. 90:2002;195-229.
104. Tam J.P., Yu Q., Lu Y.A. Tandem peptide ligation for synthetic and natural biologicals. Biologicals. 29:2001;189-196.
105. Kawamura K.S., Su R.-C., Nguyen L.T., Elford A.R., Ohashi P.S., Gariépy J. In vivo generation of cytotoxic T cells from epitopes displayed on peptide-based delivery vehicles. J. Immunol. 168:2002;5709-5715.
106. Kublin J.G., Lowitt M.H., Hamilton R.G., Oliveira G.A., Nardin E.H., Nussenzweig R.S., Schmeckpeper B.J., Diggs C.L., Bodison S.A., Edelman R. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine. 20:2002;1853-1861.
107. Demotz S., Moulon C., Roggero M.A., Fasel N., Masina S. Native-like, long synthetic peptides as components of sub-unit vaccines: practical and theoretical considerations for their use in humans. Mol. Immunol. 38:2001;415-422.
108. Perlaza B.L., Sauzet J.-P., Balde A.T., Brahimi K., Tall A., Corradin G., Druilhe P. Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice. Eur. J. Immunol. 31:2001;2200-2220.
109. Alexander J., Oseroff C., Dahlberg C., Qin M., Ishioka G., Beebe M., Fikes J., Newman M., Chesnut R.W., Morton P.A.et al. A decaepitope polypeptide primes for multiple CD8+ IFN- and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine eelivery. J. Immunol. 168:2002;6189-6198.
110. Tsuji M., Zavala F. Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites. Mol. Immunol. 38:2001;433-442.
111. Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R., van der Burg S.H., Melief C.J. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169:2002;350-358.
112. Melief C.J., Van Der Burg S.H., Toes R.E., Ossendorp F., Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188:2002;177-182 An interesting study, integrating different approaches for the optimization of vaccine design.
113. La Rosa C., Wang Z., Brewer J.C., Lacey S.F., Villacres M.C., Sharan R., Krishnan R., Crooks M., Markel S., Maas R., Diamond D.J. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood. 100:2002;3681-3689.
114. Shankar P., Schlom J., Hodge J.W. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). Vaccine. 20:2001;744-755.
115. Hodge J.W., Grosenbach D.W., Rad A.N., Giuliano M., Sabzevari H., Schlom J. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine. 19:2001;3552-3567.
116. Ninomiya A., Ogasawara K., Kajino K., Takada A., Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine. 20:2002;3123-3129.
117. Chikh G.G., Kong S., Bally M.B., Meunier J.-C., Schutze-Redelmeier M.-P.M. Efficient delivery of antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J. Immunol. 167:2001;6462-6470.
118. Lu J., Wettstein P.J., Higashimoto Y., Appella E., Celis E. TAP independent presentation of CTL epitopes by trojan antigens. J. Immunol. 166:2001;7063-7071.
119. Rodriguez F., Harkins S., Redwine J.M., Pereda J.M., Whitton J.L. CD4+ T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J. Virol. 75:2001;10421-10430.
120. Leifert J.A., Harkins S., Whitton J.L. Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther. 9:2002;1422-1428.
121. •].
122. Wolchok J.D., Livingston P.O. Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol. 2:2001;205.
123. •] are all good reviews of the results of recent clinical trials.
124. Okuno M., Kojima S., Akita K., Matsushima-Nishiwaki R., Adachi S., Sano T., Takano Y., Takai K., Obora A., Yasuda I.et al. Retinoids in liver fibrosis and cancer. Frontiers Biosci. 7:2002;204-218.
125. Disis M.L., Knutson K.L., McNeel D.G., Davis D., Schiffman K. Clinical translation of peptide-based vaccine trials: the HER-2/neu model. Crit. Rev Immunol. 21:2001;263-274.
126. Gnjatic S., Jäger E., Chen W., Altorki N.K., Matsuo M., Lee S.-Y., Chen Q., Nagata Y., Atanackovic D., Chen Y.-T.et al. CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc. Natl. Acad. Sci. U.S.A. 99:2002;11813-11818.
127. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., Woerl P., Bender A., Feuerstein B., Fritsch P.O., Romani N., Schuler G. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195:2002;1279-1288.
128. Slingluff C.L. Jr., Yamshchikov G., Neese P., Galavotti H., Eastham S., Engelhard V.H., Kittlesen D., Deacon D., Hibbitts S., Grosh W.W.et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7:2001;3012-3024.
129. Lee P., Wang F., Kuniyoshi J., Rubio V., Stuges T., Groshen S., Gee C., Lau R., Jeffery G., Margolin K.et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19:2001;3836-3847.
130. •].
131. Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A., Knutson K.L., Schiffman K. Generation of T-cell immunity to the HER-2/neu
132. Coulie P.G., Karanikas V., Colau D., Lurquin C., Landry C., Marchand M., Dorval T., Brichard V., Boon T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10290-10295.
133. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A., Davis M.M., Engleman E.G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8809-8814.